Novel Oral Anticoagulants at 10: An Assessment of their Safety and Contemporary Use in Atrial Fibrillation
Published: 04 March 2021
In this virtual roundtable, our expert panel reflect on the clinical trials and real world data supporting the use of NOACs in atrial fibrillation – almost ten years since they entered the clinic.
Moderated by Prof John Eikelboom, the panel offer their analyses via a series of presentations and discussions covering a range of topics, with a special focus on their use in Japan.
- Identify which individuals with atrial fibrillation should be initiated on NOAC therapy without delay
- Interpret safety and cardiovascular data from RCTs in the context of real-world experience
- Select appropriate treatment strategies with NOACs in atrial fibrillation patients in need of further ablation or intervention
- Review the reversal options open to individuals experiencing a bleeding event whilst on treatment with a NOAC
- Interventional Cardiologists
More from this programme
When to Initiate a NOAC and Patient Suitability (data presentation)
Overview of Safety and Cardiovascular Data
Dealing with Complications:
Discussion on Safety Rates and Patient Suitability (Panel Discussion Session)
NOAC Use with Ablation and Intervention
Prof. Ken Okumura served as a Professor of Medicine at Hirosaki University School of Medicine from 1996 to 2016. He also served as a President of the Japanese Heart Rhythm Society (JHRS) from 2012 to 2016. He is now working at Saiseikai Kumamoto Hospital Cardiovascular Center, Japan, while providing the latest interventional treatments for cardiac arrhythmias especially catheter ablation of AF. His main interests include pharmacological and non-pharmacological treatments of cardiac arrhythmias, catheter ablation of persistent AF, and oral anticoagulant therapy for stroke prevention in AF especially in the elderly AF patients.